[Analgesic-antispasmodic effect and safety of lysine clonixinate and L-hyoscinbutylbromide in the treatment of dysmenorrhea].
The purpose of this longitudinal open but not comparative study was to confirm the safety and efficacy of Lysine clonixinate (125 mg) and hyoscinbutylbromide (10 mg) capsules, during a period of observation of there menstrual cycles on 30 women with uterine dysfunction due to primary or secondary dysmenorrhea. The time of evolution for primary dysmenorrhea was of 4.46 years, and for secondary was of 1.77 years. Some associated manifestations of dysmenorrhea were: nausea (92%), vomit (92%), general pain (82.1%), abdominal pain (85.7%) and headache (46.4%). Regarding to the menstrual pain intensity, at first was highly severe in 10.7% severe in 42.9%, and moderate in 46.4%. At the end of the study, only 1 of 28 patients showed menstrual pain of moderate intensity. Only three adverse effects of light intensity were found without needing treatment, related to the manifestations of gastralgia and sleepiness. The association of a spasmolytic analgesic (Lysine clonixinate and hyoscinbutylbromide bromide) on the treatment for primary or secondary dysmenorrhea, reduces and prevents the menstrual pain (colic) as well as the associated manifestations with few spasmolytic association is efficacy and safety.
Hernández Bueno
J A
JA
Hospital Ciudad Satélite Hospital de la Mujer, S.S.A. Centro Médico 20 de Noviembre, ISSSTE.
de la Jara Díaz
J
J
Sedeño Cruz
F
F
Llorens Torres
F
F
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D002086:Butylscopolammonium Bromide / Q000008:administration & dosage / Q000627:therapeutic use*; D003002:Clonixin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004412:Dysmenorrhea / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008597:Menstrual Cycle; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*
D000700:Analgesics; D016861:Cyclooxygenase Inhibitors; D018727:Muscarinic Antagonists; D010276:Parasympatholytics; C089163:lysine clonixinate; D002086:Butylscopolammonium Bromide; D008239:Lysine; D003002:Clonixin
Efecto analgésico antiespasmódico y seguridad del clonixinato de lisina y bromuro de L-butilhioscina en el tratamiento oral de la dismenorrea.